Abiopharma

🔍 RAIGUEL DARREN S (Executive)

Company: EPLUS INC (PLUS)

Report Date: 2026-08-10

Detailed Transactions and Holdings:

• Sold 401 shares of Common Stock at $90.4395 per share (Direct)
  Date: 2026-08-10 | Code: S | equity_swap_involved: false | shares_owned_after: 68,635.00 | transaction_form_type: 4 | Footnotes: F1, F3, F2
• Sold 599 shares of Common Stock at $91.0867 per share (Direct)
  Date: 2026-08-10 | Code: S | equity_swap_involved: false | shares_owned_after: 68,036.00 | transaction_form_type: 4 | Footnotes: F1, F4, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-10 | Code: H | shares_owned_after: 35,427.00

Footnotes:

• F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.
• F2: The shares are held in a revocable trust, of which the reporting person and his spouse are the sole trustees and beneficiaries.
• F3: The transaction was executed in multiple trades at prices ranging from $89.91 to $90.89 per share, inclusive. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased and prices at which the transaction was effected.
• F4: The transaction was executed in multiple trades at prices ranging from $90.91 to $91.42 per share, inclusive. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased and prices at which the transaction was effected.